TiumBio Co (XKRX:321550) Debt-to-Asset : 0.24 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is TiumBio Co Debt-to-Asset?

TiumBio Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩5,765 Mil. TiumBio Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩23,235 Mil. TiumBio Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was ₩119,546 Mil. TiumBio Co's debt to asset for the quarter that ended in Dec. 2023 was 0.24.

TiumBio Co Debt-to-Asset Historical Data

The historical data trend for TiumBio Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TiumBio Co Debt-to-Asset Chart

TiumBio Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.17

0.24

TiumBio Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.24	0.25	0.29	0.33	0.24

Competitive Comparison of TiumBio Co's Debt-to-Asset

For the Biotechnology subindustry, TiumBio Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TiumBio Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TiumBio Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where TiumBio Co's Debt-to-Asset falls into.

TiumBio Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

TiumBio Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5764.561	+	23235.387)	/	119546.025
	=	0.24

TiumBio Co's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5764.561	+	23235.387)	/	119546.025
	=	0.24

TiumBio Co (XKRX:321550) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

TiumBio Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of TiumBio Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

TiumBio Co (XKRX:321550) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TiumBio Co Ltd (XKRX:321550) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

49, Daewangpangyo-ro 644beon-gil, Bundang-gu, 4th floor, Gyeonggi, Seongnam, KOR, 13493

Website

http://www.tiumbio.com

TiumBio Co Ltd is a Biopharmaceutical company. It is engaged in research and development of rare and intractable diseases. The company's products are in pipeline. It offers products such as Idiopathic pulmonary fibrosis therapies, immune chemotherapy, endometriosis therapies, hemophilia.

TiumBio Co (XKRX:321550) Headlines

No Headlines